Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Perrone

Showing results (171-180 of 272) with videos related to

Pageof 28
Sort By:
Cells|April 11, 2020
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of ExperienceDaniela Califano, Daniela Russo, Giosuè Scognamiglio, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research studyAlessandro Rossi, Giacomo Aimar, Marco Audisio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 studyGiuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trialAlessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
Gynecologic Oncology|March 25, 2023
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trialLucia Musacchio, Margherita Turinetto, Laura Arenare, et al.
Oncotarget|September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patientsLucia Kim, Mauro Saieg, Massimo Di Maio, et al.
Eclinicalmedicine|October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendationsAlberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
BMC Cancer|May 14, 2021
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trialsPiera Gargiulo, Laura Arenare, Cesare Gridelli, et al.
Diagnostics (Basel, Switzerland)|September 23, 2022
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus BevacizumabMarina Fabbi, Delfina Costa, Daniela Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trialsCesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Pageof 28

Showing results (171-180 of 272) with videos related to

Sort By:
Pageof 28
Cells|April 11, 2020
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of ExperienceDaniela Califano, Daniela Russo, Giosuè Scognamiglio, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2023
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research studyAlessandro Rossi, Giacomo Aimar, Marco Audisio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2010
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 studyGiuseppe Colucci, Roberto Labianca, Francesco Di Costanzo, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trialAlessandro Morabito, Gennaro Daniele, Raffaele Costanzo, et al.
Gynecologic Oncology|March 25, 2023
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trialLucia Musacchio, Margherita Turinetto, Laura Arenare, et al.
Oncotarget|September 17, 2017
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib <i>versus</i> chemotherapy in advanced non-small cell lung cancer patientsLucia Kim, Mauro Saieg, Massimo Di Maio, et al.
Eclinicalmedicine|October 25, 2023
Position paper of the Italian association of medical oncology on health disparities among transgender and gender-diverse people: the Assisi recommendationsAlberto Giovanni Leone, Raffaella Casolino, Dario Trapani, et al.
BMC Cancer|May 14, 2021
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trialsPiera Gargiulo, Laura Arenare, Cesare Gridelli, et al.
Diagnostics (Basel, Switzerland)|September 23, 2022
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus BevacizumabMarina Fabbi, Delfina Costa, Daniela Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trialsCesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Pageof 28